Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 9/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540359 | 0.83 | CA1 (0.43) | DGAT1LPLLIPGAAK1CA1 | |
| SCHEMBL22712556 | 0.83 | DGAT1 (0.59) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL29367270 | 0.83 | DGAT1 (0.59) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL2584006 | 0.82 | DGAT1 (0.58) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL29631065 | 0.82 | DGAT1 (0.58) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL2066133 | 0.81 | DGAT1 (0.56) | DGAT1FFAR1LPLLIPGCA1 | |
| SCHEMBL22086013 | 0.81 | DGAT1 (0.60) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL4046507 | 0.81 | DGAT1 (0.57) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL29520942 | 0.80 | DGAT1 (0.47) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL16554154 | 0.80 | DGAT1 (0.47) | DGAT1FFAR1LPLLIPGAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | DGAT1 4032/4885FFAR1 597/4885LPL 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.